Prof. Dr. AHMET DEMİRKAZIK

Yayın Ağı

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler 87

1. Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: Case report and literature review

ERDOĞAN S., PEKER E., Demirkazık A., Aydın N., YÜCESAN C.

Journal of Neuroimmunology , cilt.406, 2025 (SCI-Expanded)

2. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach

Bozcuk H. S., Sert L., Kaplan M. A., TATLI A. M., KARACA M., MUĞLU H., et al.

CANCERS , cilt.17, sa.2, 2025 (SCI-Expanded)

3. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

KAHRAMAN S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., SUCUOĞLU İŞLEYEN Z., et al.

SCIENTIFIC REPORTS , cilt.14, sa.1, 2024 (SCI-Expanded)

4. Long-Term outcomes of intensity-modulated radiotherapy in limited-stage small-cell lung cancer classified according to AJCC 8th tumor node metastasis staging system

DURU BİRGİ S., ÖZ S., BABAYİĞİT Y., KÖKSOY E. B., DEMİRKAZIK A., AKYÜREK S.

European Review for Medical and Pharmacological Sciences , cilt.28, sa.4, ss.1562-1574, 2024 (SCI-Expanded)

5. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

Karadurmus N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., et al.

Current Medical Research and Opinion , cilt.40, sa.7, ss.1171-1178, 2024 (SCI-Expanded)

6. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer

Alkan A., Mizrak D., Yaşar A., Karci E., KÖKSOY E. B., Ürün M., et al.

Journal of Cancer Research and Therapeutics , cilt.20, sa.3, ss.913-917, 2024 (SCI-Expanded)

7. Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.

KARAOĞLAN B. B., Yekedüz E., YAZGAN S. C., Mocan E. E., KÖKSOY E. B., YAŞAR H. A., et al.

Immunotherapy , cilt.16, sa.12, ss.821-828, 2024 (SCI-Expanded)

8. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Güner G., Aktaş B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., et al.

Journal of cancer research and clinical oncology , cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded)

9. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

GÜRSOY P., TATLI A. M., Erdem D., GÖKER E., Celik E., Demirci N. S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.2, ss.865-875, 2023 (SCI-Expanded)

10. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gürbüz M., Kutlu Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded)

11. Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors

Yekeduz E., KÖKSOY E. B., YAZGAN S. C., KARATAŞ G., ÇAY ŞENLER F., UTKAN G., et al.

ANTI-CANCER DRUGS , cilt.33, sa.10, ss.1145-1149, 2022 (SCI-Expanded)

12. Lung Cancer in Turkey.

Cangır A. K., Yumuk P. F., Sak S. D., Akyürek S., Eralp Y., Yılmaz Ü., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , cilt.17, sa.10, ss.1158-1170, 2022 (SCI-Expanded)

13. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., et al.

MEDICINE , cilt.101, sa.34, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

14. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

15. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., ŞENDUR M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

16. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.

JOURNAL OF BUON , cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

17. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded)

18. Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Kilickap S., Demirci U., Bugdayci F., Tural D., Korkmaz T., Paydas S., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.14, sa.10, 2019 (SCI-Expanded)

19. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Eralp Y., Ak N., Yilmazbayhan D., Ozkan B., Ferhatoglu F., DEMİRKAZIK A., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.14, sa.10, 2019 (SCI-Expanded)

20. Ga-68-DOTATATE Uptake in Pancreatic Metastasis of Renal Cell Carcinoma Mimicking Pancreatic Neuroendocrine Tumor

Soydal Ç., Nak D., Araz M., Demirkazık A., Küçük N. Ö.

CLINICAL NUCLEAR MEDICINE , cilt.44, sa.10, ss.795-796, 2019 (SCI-Expanded)

21. The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer

Tek I., Akbulut H., Utkan G., DEMİRKAZIK A., Senler F. C., Icli F.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded)

22. Diagnostic serum vitamin D level is not a reliable prognostic factor for resectable breast cancer

Kaya D. M., Orturk B., Kubilay P., Onur H., UTKAN G., ÇAY ŞENLER F., et al.

FUTURE ONCOLOGY , sa.15, ss.1461-1467, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

23. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Markoczy Z., Sarosi V., Kudaba I., Galffy G., Turay U. Y., DEMİRKAZIK A., et al.

BMC CANCER , cilt.18, 2018 (SCI-Expanded)

24. The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

AKBULUT H., Ocal M., Sonugur F. G., Abgarmi S. A., BABAHAN C., Akay B., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

25. Vaccination in oncology practice and predictors

Alkan A., Karci E., Yasar A., Tuncay G., KÖKSOY E. B., Urun M., et al.

SUPPORTIVE CARE IN CANCER , cilt.25, sa.9, ss.2677-2682, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma

26. Docetaxel-induced pericardial effusion

Dogan S. E., Mizrak D., Alkan A., DEMİRKAZIK A.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.23, sa.5, ss.389-391, 2017 (SCI-Expanded)

27. The significance of serum leptin level in patients with early stage nonsmall cell lung cancer

Karatas F., YALÇIN B., Sahin S., AKBULUT H., UTKAN G., DEMİRKAZIK A., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.13, sa.2, ss.204-207, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma

28. Turkish doctors' cohort: healthy despite low screening

ÜNAL S., DURUSU TANRIÖVER M., Ascioglu S., DEMİRKAZIK A., Ertenli I., Eskioglu E., et al.

POSTGRADUATE MEDICINE , cilt.129, sa.3, ss.393-398, 2017 (SCI-Expanded)

29. Medical oncologists' attitudes towards vaccination in oncology practice

Alkan A., Karci E., Yasar A., Tuncay G., Urun M., Koksoy E. B., et al.

ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

30. Typing of non-small cell lung carcinoma and investigation of enteric differentiation in small biopsy specimens

Erol A., Percinel S., DEMİRKAZIK A.

ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded)

31. The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC)

AKBULUT H., Ocal M., Sonugur G., AKAY B. N., BABAHAN C., Abgarmi S. A., et al.

ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

32. Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

ARTAÇ M., COŞKUN H. Ş., Korkmaz L., Kocer M., Turhal N. S., ENGİN H., et al.

CLINICAL GENITOURINARY CANCER , cilt.14, sa.4, 2016 (SCI-Expanded)

33. Molecular Spectrum of PIK3CA Gene Mutations in Patients with Nonsmall-Cell Lung Cancer in Turkey

EKİNCİ S., ILGIN RUHİ H., Dogan M., Gursoy S., SAK S., DEMİRKAZIK A., et al.

GENETIC TESTING AND MOLECULAR BIOMARKERS , cilt.19, sa.7, ss.353-358, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

34. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer

Geredeli C., ARTAÇ M., Yildirim S., Inal A., Dede I., Guler T., et al.

TUMOR BIOLOGY , cilt.36, sa.6, ss.4279-4285, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

35. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer

ÜRÜN Y., UTKAN G., Yalcin B., AKBULUT H., Onur H., Oztuna D., et al.

Experimental Oncology , cilt.37, sa.1, ss.53-57, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

36. THE PROGNOSTIC ROLE OF XRCC1, ERCC1, ERCC2, AND TP53 SINGLE NUCLEOTIDE POLYMORPHISMS IN RESECTED NON-SMALL-CELL LUNG CANCER

Geredeli C., Artac M., Yildirim S., Dede I., Inal A., Guler T., et al.

EUROPEAN JOURNAL OF CANCER , cilt.50, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

37. The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey

Dogan M., DEMİRKAZIK A., Tukun A., SAK S., CEYHAN K., Yalcin B., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.1, ss.1-10, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

38. Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members

ÜRÜN Y., AKBULUT H., DEMİRKAZIK A., Senler F. C., Utkan G., Onur H., et al.

JOURNAL OF BUON , cilt.18, sa.2, ss.511-515, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

39. Intraabdominal follicular dendritic cell sarcoma: A report of three cases and review of the literature

ÜRÜN Y., Kankaya D., Koral L., YALÇIN B., Karabork A., CEYHAN K., et al.

Tumori , cilt.99, sa.2, 2013 (SCI-Expanded)

40. Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey

ÜRÜN Y., UTKAN G., KAYI CANGIR A., Oksuzoglu O. B., Ozdemir N., Oztuna D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , sa.5, ss.2801-2803, 2013 (SCI-Expanded)

41. ABO and Rh blood groups frequency in women with HER2 positive breast cancer

ÜRÜN Y., Utkan G., Altundag K., Arslan O., Onur H., Arslan U. Y., et al.

JOURNAL OF BUON , cilt.17, sa.3, ss.457-460, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

42. Characteristics of Oropharyngeal Candida and Bacterial Colonization in Cancer Patients

ÇAY ŞENLER F., Cakmakci S., Akan O. A., DEMİRKAZIK A., AKBULUT H., Icli F.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.2, ss.113-119, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

43. Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients

Dogan M., KARABULUT H. G., Tukun A., DEMİRKAZIK A., UTKAN G., Yalcin B., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.4, ss.1553-1556, 2012 (SCI-Expanded)

44. Albumin Infusion is not Beneficial in Hypoalbuminemic End-Stage Cancer Patients: A Matched-Pair Analysis

Buyukcelik A., DEMİRKAZIK A., YALÇIN B., Dogan M., Kavgaci H., Coban S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.4, ss.213-219, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

45. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

Icli F., AKBULUT H., Onur H., Yalcin B., DEMİRKAZIK A., ÇAY ŞENLER F.

BREAST , cilt.20, sa.2, ss.155-157, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

46. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP

Dincol D., Buyukcelik A., Dogan M., AKBULUT H., Samur M., DEMİRKAZIK A., et al.

MEDICAL ONCOLOGY , cilt.27, sa.3, ss.942-945, 2010 (SCI-Expanded)

47. The Prognostic Importance of Leucocytosis, Thrombocytosis and Serum Vascular Endothelial Growth Factor (VEGF) Level in Inoperable Non-Small Cell Lung Cancer (NSCLC): A Match-Pair Analysis

DEMİRKAZIK A., Asik M., Yalcin B., Dogan M., Buyukcelik A., Sencan O., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.1, ss.14-19, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

48. Myoid Hamartoma of the Breast: A Very Rare Entity

BAYAR S., DÜŞÜNCELİ ATMAN E., HEPER A., Guner R., GENÇ V., DEMİRKAZIK A.

BREAST JOURNAL , cilt.16, sa.1, ss.86-88, 2010 (SCI-Expanded)

49. Individualized therapy in cancer: Why pharmacogenetics? Kanserde Bireyselleştirilmiş Tedavi: Neden Farmakogenetik?

DEMİRKAZIK A., Tükün F. A.

Turkiye Klinikleri Journal of Medical Sciences , cilt.30, sa.3 SUPPL., 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

50. Effects of Genomic Imbalances on Telomerase Activity in Gastric Cancer: Clues to Telomerase Regulation

GÜMÜŞ AKAY G., ELHAN A. H., ÜNAL A. E., DEMİRKAZIK A., SUNGUROĞLU A., Tukun A.

ONCOLOGY RESEARCH , cilt.17, sa.10, ss.455-462, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

51. Role of ABCB1 and ABCC1 Gene Induction on Survival in Locally Advanced Breast Cancer

Atalay C., DEMİRKAZIK A., Gunduz U.

JOURNAL OF CHEMOTHERAPY , cilt.20, sa.6, ss.734-739, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

52. Mill of non-neoplastic cranial complications of malignant disorders

Yagmurlu B., AKYÜREK S., FİTOZ Ö. S., DEMİRKAZIK A.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , cilt.14, sa.2, ss.61-68, 2008 (SCI-Expanded)

53. MRI of non-neoplastic cranial complications of malignant disorders

Yaǧmurlu B., AKYÜREK S., FİTOZ Ö. S., DEMİRKAZIK A.

Diagnostic and Interventional Radiology , cilt.14, sa.2, ss.61-68, 2008 (SCI-Expanded)

54. Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas

Yaman E., Yalcin B., Utkan G., AKBULUT H., Isikdogan A., Sencan O., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.18, sa.2, ss.79-84, 2008 (SCI-Expanded)

55. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.

Sencan O., Buyukcelik A., Yalcin B., Boruban M. C., AKBULUT H., DEMİRKAZIK A., et al.

European journal of cancer care , cilt.17, sa.1, ss.26-32, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

56. Symptoms or signs due to different chemotherapeutics and their relationship with serum cytokines/VEGF levels in patients with cancer

DEMİRKAZIK A., Yilmaz H., AKBULUT H., Yalcin B., Icli F.

JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

57. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

Icli F., AKBULUT H., Utkan G., Yalcin B., Dincol D., Isikdogan A., et al.

JOURNAL OF SURGICAL ONCOLOGY , cilt.95, sa.6, ss.507-512, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

58. Lung cancer metastasis mimicking gluteal abscess

Tek I., Iyidir O. T., Utkan G., Ceyhan K., Buyukcelik A., Yalcin B., et al.

SOUTHERN MEDICAL JOURNAL , cilt.100, sa.3, ss.334-335, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

59. Case report: Ultrasound-guided percutaneous laser ablation treatment in inoperable aggressive course anaplastic thyroid carcinoma: The introduction of a novel alternative palliative thepapy - Second experience in the literature

Cakir B., Topaloglu O., Gul K., Agac T., Aydin C., Dirikoc A., et al.

HORMONE RESEARCH , cilt.68, ss.40, 2007 (SCI-Expanded)

60. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.

Utkan G., Bueyuekcelik A., Yalcin B., AKBULUT H., DEMİRKAZIK A., Dincol D., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.53, sa.3, ss.367-74, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma

61. An unspecified neurologic paraneoplastic syndrome pointing out an occult relapse of ovarian cancer: A case report

Büyükçelik A., DEMİRKAZIK A., Yalçin B., Şener Ö., UTKAN G., Tulunay G., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.15, sa.4, ss.199-202, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma

62. Interferon-alpha as maintenance therapy in patients with multiple myeloma

Yalcin B., Dogan M., Buyukcelik A., Doruk H., Tek I., DEMİRKAZIK A.

ANNALS OF ONCOLOGY , cilt.16, sa.12, ss.1981, 2005 (SCI-Expanded)

63. Combination chemotherapy of gemcitabine and vinorelbine in patients with advanced non-small cell lung cancer

Buyukcelik A., Utkan G., Yalcin B., DEMİRKAZIK A.

LUNG CANCER , cilt.46, sa.3, ss.377-378, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

64. Serum vascular endothelial growth factor levels in patients with nonsmall, cell lung cancer

DEMİRKAZIK A., AKBULUT H., Ulger A., Arican A., Ozer I., Acikgoz N., et al.

ANNALS OF SAUDI MEDICINE , cilt.24, sa.6, ss.473-475, 2004 (SCI-Expanded)

65. Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma

AKBULUT H., Icli F., Yalcin B., DEMİRKAZIK A., Onur H., Buyukcelik A., et al.

EXPERIMENTAL ONCOLOGY , cilt.26, sa.2, ss.149-152, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

66. A new schedule of mitomycin-C and vinorelbine combination in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes: A phase II study

Yalcin B., ÜNER A., AKBULUT H., Icli F., Buyukcelik A., Isikdogan A., et al.

ANNALS OF ONCOLOGY , cilt.15, ss.42, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

67. The relationship between vascular endothelial growth factor (VEGF) levels and the prognostic importance of leucocytosis and thrombocytosis and its relationship with vegf levels in inoperable non-small cell lung cancer

DEMİRKAZIK A., Asik M., Yalcin B., Buyukcelik A., Akbulul H., Icli F.

ANNALS OF ONCOLOGY , cilt.15, ss.195, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

68. The prognostic Importance of Venous Thromboembolism (VT) in cancer patients and its relationship with the ieveis of factor VIII and Vascular Endothelial Growth Factor (VEGF)

DEMİRKAZIK A., Dogan M., Konuk N., AKBULUT H., Yalcin B., Buyukcelik A., et al.

ANNALS OF ONCOLOGY , cilt.15, ss.151, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma

69. A randomized trial of four cycles of adjuvant AC (adriamycin plus cyclophosphamide) +/- two cycles of EP (etoposide plus cisplatin) in node positive patients with breast cancer

Icli F., AKBULUT H., Dincol D., Onur H., DEMİRKAZIK A., Cam R., et al.

ANNALS OF ONCOLOGY , cilt.12, sa.7, ss.1011-1013, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

70. Comparison of 5-fluorouracil-folinic acid and etoposide-doxorubicin-cisplatin chemotherapies in patients with advanced gastric carcinoma: A prospective randomized crossover study, interim analysis.

Sencan O., DEMİRKAZIK A., AKBULUT H., Yalcin B., Icli F.

ANNALS OF ONCOLOGY , cilt.11, ss.70-71, 2000 (SCI-Expanded)

71. The efficacy of irinotecan, cisplatin and dacarbazine combination in patients with metastatic colorectal cancer resistant to 5-fluorouracil.

AKBULUT H., Icli F., DEMİRKAZIK A., Yalcin B., Buyukcelik A., Cay F.

ANNALS OF ONCOLOGY , cilt.11, ss.46, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

72. Clinicopathologic features and prognostic factors of primary extranodal non-Hodgkin's lymphomas in Turkey

Arican A., Dincol D., Akbulut H., Onur H., DEMİRKAZIK A., Cay F., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.6, ss.587-592, 1999 (SCI-Expanded)

73. The effect of two different doses of oral clodronate on pain in patients with bone metastases

Arican A., Içli F., AKBULUT H., Çakir M., Sencan O., Samur M., et al.

MEDICAL ONCOLOGY , cilt.16, sa.3, ss.204-210, 1999 (SCI-Expanded)

74. Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil

Icli F., Arican A., Cay F., AKBULUT H., Dincol D., Karaoguz H., et al.

ONCOLOGY , cilt.56, sa.4, ss.297-300, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

75. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

Icli F., ÇELİK İ., Aykan F., Uner A., DEMİRKAZIK A., Ozet A., et al.

CANCER , cilt.83, sa.12, ss.2475-2480, 1998 (SCI-Expanded)

76. Cisplatin and epirubicin induction chemotherapy followed by chemoradiotherapy in limited stage small cell lung cancer (LS-SCLC)

Cay F., Onat H., Saip P., Kars A., DEMİRKAZIK A., AKBULUT H., et al.

ANNALS OF ONCOLOGY , cilt.9, ss.104, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

77. Diagnostic value of ferritin in the differential diagnosis of malignant effusions

DEMİRKAZIK A., Dinçol D., Hastürk S., Arican A., Karaoǧuz H., Çay F., et al.

Cancer Biochemistry Biophysics , cilt.16, sa.3, ss.243-251, 1998 (SCI-Expanded)

78. Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy

AYDİN F., DEMİRKAZIK A., Içli F., AKBULUT H., Samur M.

Journal of Chemotherapy , cilt.10, sa.5, ss.394-398, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

79. Surgical resection followed by adjuvant chemotherapy in small cell lung cancer with limited disease

Arican A., Dincol D., AKBULUT H., Cay F., Icli F., Karaoguz H., et al.

ANNALS OF ONCOLOGY , cilt.9, ss.105-106, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

80. High dose epirubicin and cisplatin induction chemotherapy sequentially followed by ifosfamide and etoposide chemotherapy in extensive stage small cell lung cancer (ES-SCLC)

DEMİRKAZIK A., Onat H., Saip P., Ozguroglu M., Kars A., Cay F., et al.

ANNALS OF ONCOLOGY , cilt.9, ss.105, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

81. Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP)+/-bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey

Dincol D., AKBULUT H., Icli F., Samur M., Karaoguz H., DEMİRKAZIK A., et al.

ONCOLOGY , cilt.54, sa.5, ss.376-379, 1997 (SCI-Expanded)

82. Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric

Icli F., Karaoguz H., AKBULUT H., Dincol D., DEMİRKAZIK A., Cay F.

JOURNAL OF SURGICAL ONCOLOGY , cilt.64, sa.4, ss.318-323, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

83. Two dose levels of ifosfamide in malignant mesothelioma

Icli F., Karaoguz H., Hasturk S., Kurt B., AKBULUT H., Dincol D., et al.

LUNG CANCER , cilt.15, sa.2, ss.207-213, 1996 (SCI-Expanded)

84. MESNA IFOSFAMIDE, MITOXANTRONE, ETOPOSIDE, BLEOMYCIN, VINCRISTINE, PREDNISONE (MINE-BOP) COMBINATION CHEMOTHERAPY IN THE TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS-LYMPHOMA

DINCOL D., ICLI F., KARAOGUZ H., CAY F., ARICAN A., DEMİRKAZIK A., et al.

ACTA ONCOLOGICA , cilt.34, sa.7, ss.937-940, 1995 (SCI-Expanded)

85. PRIMARY GASTROINTESTINAL LYMPHOMAS IN TURKEY - A RETROSPECTIVE ANALYSIS OF CLINICAL-FEATURES AND RESULTS OF TREATMENT

DINCOL D., ICLI F., EREKUL S., GUNEL N., KARAOGUZ H., DEMİRKAZIK A.

JOURNAL OF SURGICAL ONCOLOGY , cilt.51, sa.4, ss.270-273, 1992 (SCI-Expanded)

86. CISPLATIN PLUS VP-16 COMBINATION CHEMOTHERAPY IN ADVANCED REFRACTORY BREAST-CANCER

ICLI F., GUNEL N., DINCOL D., KARAOGUZ H., DEMİRKAZIK A.

JOURNAL OF SURGICAL ONCOLOGY , cilt.50, sa.4, ss.251-253, 1992 (SCI-Expanded) Sürdürülebilir Kalkınma

87. TREATMENT OF METASTATIC MALIGNANT-MELANOMA WITH 24 HOURS CONTINUOUS VENOUS INFUSION OF DACARBAZINE AND CISPLATIN

ICLI F., KARAOGUZ H., DINCOL D., GUNEL N., DEMİRKAZIK A.

JOURNAL OF SURGICAL ONCOLOGY , cilt.48, sa.3, ss.199-201, 1991 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler 21

1. Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

Ozgun A., Mustafayev F. N. A., Dogan I., Vatansever S., Eryilmaz M. K., ERDOĞAN A. P., et al.

MOLECULAR AND CLINICAL ONCOLOGY , cilt.22, sa.6, 2025 (ESCI)

2. Radyoaktif İyot Dirençli Diferansiye Tiroid Kanserinde Sorafenib: Uzun Dönem Tecrübe ile Gerçek Yaşam Verisi

Yekedüz E., Köksoy E. B., Şenler F., Akbulut H., Demirkazık A., Ürün Y., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.75, sa.1, ss.103-106, 2022 (Hakemli Dergi)

3. The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer

Gurbuz M., DOĞAN İ., AKKUŞ E., ÖZAKINCI H., Tolunay P., KALACI E., et al.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , cilt.70, sa.2, ss.132-140, 2022 (ESCI)

4. Seasonal influenza and pneumococcal vaccination rates among patients with cancer in covid-19 pandemic: A cross-sectional study

Yekedüz E., KÖKSOY E. B., YAZGAN S. C., AKBIYIK I., BALLI S., Kavak E. E., et al.

Journal of Oncological Science , cilt.7, sa.2, ss.64-70, 2021 (Scopus)

5. Association between blood type and epidermal growth factor receptor mutation positivity in lung adenocarcinoma patients

Gürbüz M., AKKUŞ E., Karaalioğlu B., Aktaş E. G., KÖKSOY E. B., ÖZAKINCI H., et al.

Journal of Oncological Science , cilt.7, sa.1, ss.20-24, 2021 (Scopus)

6. Sleep Quality of Cancer Patients Receiving Systemic Treatment: A Cross-Sectional Study

TUNCA Ş. N., ŞAHİN M. A., DEMİRKAZIK A., ÖZKAN A., ÇAY ŞENLER F.

Journal of Oncological Sciences , cilt.6, sa.1, ss.15-22, 2020 (Hakemli Dergi) Sürdürülebilir Kalkınma

7. Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome

Keskin H., Cadirci K., Demirkazık A., Akbulut H., Yalçın B.

Biomarkers in Cancer , cilt.11, 2019 (Hakemli Dergi)

8. Baseline data of a prospective cohort study: Cappadocia cohort study, Turkey

ÜNAL S., AŞÇIOĞLU HAYRAN S., DEMİRKAZIK A., ERTENLİ A. İ., eskioğlu e., GÜLER K., et al.

Türkiye Halk Sağlığı Dergisi , cilt.16, sa.3, ss.190-203, 2018 (Hakemli Dergi)

9. Ga-68 PSMA Accumulation in Hepatocellular Carcinoma

SOYDAL Ç., ALKAN A., ÖZKAN E., DEMİRKAZIK A., KÜÇÜK N. Ö.

Journal of Gastroenterology, Pancreatology Liver Disorders , cilt.4, sa.2, ss.1, 2017 (Hakemli Dergi)

10. Fight of Turkish medical oncologists against cancer: Focus on two societies: Turkish Society of Medical Oncology and Turkish Oncology Group

ABALI H., DEMİRKAZIK A.

Journal of Oncological Sciences , cilt.3, sa.1, ss.1-2, 2017 (Hakemli Dergi) Sürdürülebilir Kalkınma

11. Turkish medical oncology society looks forward

DEMİRKAZIK A.

Journal of Oncological Science , cilt.1, 2016 (Hakemli Dergi)

12. Quality of life assesment in patients with non-small cell lung cancer patients who have or have not received second line chemotherapy

DEMİRKAZIK A.

Acta Oncologica Turcica , cilt.48, sa.2, ss.53-62, 2015 (Hakemli Dergi) Sürdürülebilir Kalkınma

13. Malign mesothelioma and gelatinous pleural fluid

KARNAK D., Sözener Z. ç., Uçar Y., Cangir A., DEMİRKAZIK A., Kankaya D.

Asian Pacific Journal of Tropical Disease , cilt.1, sa.1, ss.80-82, 2011 (Scopus)

14. The prognostic ımportance of leucocytosis, thrombocytosis and serum vascular endothelial growth factor (VEGF) level in ınoperable non-small cell lung cancer (NSCLC): A match-pair analysis

DEMİRKAZIK A.

Uluslararası Hematoloji Onkoloji Dergisi , cilt.20, sa.1, ss.14-19, 2010 (Scopus) Sürdürülebilir Kalkınma

15. The impact of operation center and the prognostic factors on the outcome of patients with stage II and stage III colorectal cancer

Buyukqeljk A., AKBULUT H., Yalqin B., Encan O., Tek J., Demir O., et al.

Turkish Journal of Cancer , cilt.38, sa.4, ss.175-183, 2008 (Scopus) Sürdürülebilir Kalkınma

16. Frequency of symptoms in patients with advanced cancer

Yalçin B., Büyükçelik A., Şenler F. Ç., UTKAN G., Tek I., Doǧan M., et al.

Turkish Journal of Cancer , cilt.35, sa.4, ss.177-180, 2005 (Scopus) Sürdürülebilir Kalkınma

17. Adrenal gland insufficiency in a patient with non-small cell lung cancer: Case report and review of the literature Adrenal gland yetmezliǧi gelişen bir küçük hücreli dişi akciǧer kanseri olgusu: Olgu sunumu ve literatürün gözden geçirilmesi

Büyüçelik A., UTKAN G., DEMİR Ö., Yalçin B., DEMİRKAZIK A., Içli F.

THOD - Turk Hematoloji-Onkoloji Dergisi , cilt.12, sa.4, ss.210-214, 2002 (Scopus) Sürdürülebilir Kalkınma

18. Adrenal gland yetmezliği gelişen bir küçük hücreli dışı akciğer kanseri olgusu: Olgu sunumu ve literatürün gözden geçirilmesi

DEMİRKAZIK A.

Türk Hematoloji Onkoloji Dergisi , cilt.12, sa.4, ss.210-214, 2002 (Hakemli Dergi) Sürdürülebilir Kalkınma

19. Cardiotoxicity of 5-fluorouracil: Two cases with severe bradycardia and review of the literature

Samur M., Arican A., Cakir M., Sencan O., DEMİRKAZIK A., AKBULUT H., et al.

Turkish Journal of Cancer , cilt.29, sa.1, ss.39-41, 1999 (Scopus)

20. The prognostic significance of flow cytometric cellular DNA content determination in patients with colorectal carcinoma

AKBULUT H., Dincol D., Aydintug O., Icli F., Karaoguz H., DEMİRKAZIK A., et al.

Turkish Journal of Cancer , cilt.28, sa.2, ss.51-58, 1998 (Scopus)

21. Myeloprotective effect of high dose medroxyprogesterone acetate on patients receiving cytotoxic chemotherapy

Samur M., Icli F., AKBULUT H., DEMİRKAZIK A., Cay F., Arican A.

Turkish Journal of Cancer , cilt.28, sa.3, ss.118-123, 1998 (Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 34

1. KRAS-G12C Mutant Metastatik Küçük Hücreli Dışı Akciğer Kanseri Hastalarında İmmünoterapi İle Sağkalım Sonuçlarının Değerlendirilmesi

YEKEDÜZ E., DEMİRKAZIK A.

6. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Ekim 2022, (Özet Bildiri)

2. İleri evre malignitelerde immüncheckpoint inhibitörleri ile eş zamanlı verilen antihistaminiklerin sağkalım katkısı ile ilgili gerçek yaşam verileri

EYLEMER MOCAN E., YEKEDÜZ E., KARATAŞ G., YAZGAN S. C., KÖKSOY E. B., ÇAY ŞENLER F., et al.

9. Türk Tıbbi Onkoloji Kongresi, Girne, Kıbrıs (Kktc), 18 - 22 Mayıs 2022, ss.53, (Özet Bildiri)

3. CRP/albumin oranının immün denetim noktası inhibitörü alan metastatik kanser hastalarındaki prognostik rolü

YEKEDÜZ E., YAZGAN S. C., KÖKSOY E. B., AKBULUT H., ÇAY ŞENLER F., DEMİRKAZIK A., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.108, (Özet Bildiri)

4. Letrozol ilişkili mediastinal lenfadenopatiler ve pulmoner nodüller

KÖKSOY E. B., YEKEDÜZ E., KALACI E., AKBULUT H., DEMİRKAZIK A.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.161, (Özet Bildiri)

5. Agresif B hücreli primer üreter lenfoma olgusu

KARAALİOĞLU B., YEKEDÜZ E., KALACI E., DURSUN B., DEMİRKAZIK A.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.143, (Özet Bildiri)

6. Regorafenib ile tedavi edilen nüks metastatik osteosarkom olgusu

DURSUN B., BALLI S., KALACI E., AKBIYIK I., YEKEDÜZ E., KAVAK E. E., et al.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 3 - 07 Kasım 2021, ss.183-184, (Özet Bildiri)

7. 1547 P: Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

KILIÇKAP S., BUĞDAYCI BAŞAL F., DEMİRKAZIK A., GÜRSOY P., DEMİRCİ U., ERMAN M., et al.

44th ESMO Congress (ESMO 2019), 27 Eylül - 01 Ekim 2019, cilt.30, ss.637, (Özet Bildiri)

8. Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

Kilickap S., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., Erman M., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.637, (Özet Bildiri)

9. Yalnız el parmak kemiğinde metastazı olan akciğer kanserli nadir bir olgu

GÜRBÜZ M., KUBİLAY TOLUNAY P., ÖZYURT N., YEKEDÜZ E., DEMİRKAZIK A.

23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.386-387, (Özet Bildiri)

10. Sistemik ve lokal ablatif tedaviler ile uzun süreli sağkalım elde edilmiş metastatik kolon kanseri olgusu

ÖZYURT N., GÜRBÜZ M., YAŞAR H. A., YEKEDÜZ E., KUBİLAY TOLUNAY P., KARAALİOĞLU B., et al.

23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.470, (Özet Bildiri)

11. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

Kilickap S., Olmez O. F., Cicin I., Demirci U., Alan O., Cabuk D., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.505, (Özet Bildiri)

12. Asingle center analysis of evolving experience with ALPPS procedure: Towards better patient and graft selection

BALCI D., KIRIMKER E. O., ÖZÇELİK M., ÜSTÜNER E., KONCA C., UTKAN G., et al.

12th Biennial E-AHPBA Congress 2017, Mainz, Almanya, 23 - 26 Mayıs 2017, (Özet Bildiri)

13. Future liver remnant hypertrophy with Yttrium90Radioembolization in a patient with gastric neuroendocrine tumor liver metastasis

ÇETİNKAYA Ö. A., KIRIMKER E. O., DEMİRKAZIK A., ÖZÇELİK M., BİLGİÇ M. S., ÜSTÜNER E., et al.

12th Biennial E-AHPBA Congress 2017, Mainz, Almanya, 23 - 26 Mayıs 2017, (Özet Bildiri)

14. Onkoloji pratiğinde aşılama ve etkileyen faktörler

ALKAN A., karcı E., YAŞAR H. A., Tuncay G., KÖKSOY E. B., Ürün M., et al.

22. Ulusal Kanser Kongresi, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

15. The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectalcancer mCRC

AKBULUT H., Öcal M., Sonugür G., AKAY B., Bahahan C., Abgarmi S. A., et al.

ESMO Congress, 7 - 11 Ekim 2016, (Özet Bildiri)

16. Vaccination in oncology practice and predictors

ALKAN A., KARCI E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., et al.

ESMO, 7 - 10 Ekim 2016

17. Medical oncologists attitudes towards vaccination inoncology practice

ALKAN A., karcı e., YAŞAR H. A., tuncay g., ürün m., KÖKSOY E. B., et al.

ESMO annual meeting, 7 - 11 Ekim 2016, (Özet Bildiri)

18. Adjuvant concurrent chemoradiotherapy(CRT) plus docetaxelcisplatin-fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer

Alkan A., Mizrak D., Karci E., Yasar A., Koksoy E. B., Urun M., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, (Özet Bildiri)

19. The significance of the serum leptin, ghrelin, tumor necrosis factor alpha and interleukine-1 levels in patients with non-small cell lung cancer

Karatas F., Yalcin B., AKBULUT H., Utkan G., Sahin S., DEMİRKAZIK A., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

20. Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.

AKBULUT H., Gercik O., Icli F., Mizrak D., DEMİRKAZIK A., Onur H., et al.

21. The prognostic role of XRCC1, ERCC1, ERCC2 and, TP53 single nucleotide polymorphisms (SNPs) in metastatic non-small cell lung cancer (NSCLC)

Artac M., Geredeli C., Yildirim S., Inal A., Guler T., Boruban C., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49, (Özet Bildiri) Sürdürülebilir Kalkınma

22. The prognostic role of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in resected non-small cell lung cancer (NSCLC)

Geredeli C., Artac M., Yildirim S., Dede I., Inal A., Guler T., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

23. Is anemia due to chronic disease the main cause of anemia in cancer patients?

Utkan G., Kenar G., AKBULUT H., DEMİRKAZIK A., Onur H., Icli F.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

24. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

Hanna N. H., Kaiser R., Sullivan R. N., Aren O. R., Ahn M., Tiangco B., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

25. ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

ÜRÜN Y., Koru-Sengul T., Altundag K., Utkan G., Onur H., AKBULUT H., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

26. ABO blood group and the risk of lung cancer: Multicenter, case-control, observational study

Utkan G., ÜRÜN Y., Cangir A. K., Oksuzoglu O. B., Ozdemir N., Oztuna D., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, (Özet Bildiri)

27. The Significance of the Serum Leptin Ghreline Tumor Necrosis Factor Alpha and Interleukine 1 Levels in Patient With Non Small Cell Lung Cancer

ÜRÜN Y., YALÇIN B., KARATAŞ F., UTKAN G., YÜKSEL C., CANGIR A., et al.

The 2011 European Multidisiplinary Cancer Congress. Stockholm, Sweden, Stockholm, İsveç, 24 - 27 Eylül 2011, ss.612

28. Quality of Life Assesment in Patients With Non-Small Cell Lung Cancer Patients Who Have or Have Not Received Second Line Chemotherapy

Yalcin B., Suna N., Dogan M., ÜRÜN Y., Ozdemir N., Gonullu U., et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri) Sürdürülebilir Kalkınma